Allergy Therapeutics - AGY Stream Log

"This morning Allergy Therapeutics (AGY)... announced that the results from its latest phase 2 dose range finding clinical trial for GrassMATAMPL (the development version of Pollinex® Quattro Grass) were inconclusive. As a consequence, the company is not yet able to recommend a dose to take into the final phase 3 trial as expected... We estimate these events necessitate a delay of around 1 year to the start of phase 3 development for GrassMATAMPL but do not affect any other clinical development programmes being conducted by the company (i.e. the Birch vaccine phase 3 trial)." Zeus Capital note from today on research tree

scraped a bit of panmure's note from research tree: "Allergy Therapeutics has announced the appointment of Nick Wykeman (exSkyepharma) to the Board as Finance Director with immediate effect. We view today’s appointment as a solid fit, filling the position that has been open since the announcement earlier this year, with an individual whose life sciences and wider background aligns well with the Allergy business..."

Abbott Labarotories is buying CFR Pharmaceuticals of Peru for $2.9 billion announced on Friday afternoon in New York stock exchange

CFR Pharmaceuticals owns 49% of Allergy Therapeutics sharesI wonder if that has anything to do that shares went up on Friday afternoon

Interims due tomorrow, 24th.

Welcome to the new Allergy Therapeutics stream forum! Messages posted in the Allergy Therapeutics stream will be logged here for posterity.